# A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment

Study · id `cardio:ct-nct03069365` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT03069365](<https://clinicaltrials.gov/study/NCT03069365>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT03069365

Browse, organ or system: Kidneys  
Browse, condition area: Kidney connections  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 101 participants.

## Technical summary

Registry record NCT03069365. Non-randomized; no masking; primary purpose treatment. Start 2017-03-28 (actual); primary completion 2018-02-20 (actual). Results posted on 2019-03-04.

## Key facts

- Design: Interventional study; non-randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 101 participants (enrolled count; ClinicalTrials.gov record NCT03069365, source copy `cardio:ctgov-nct03069365-2019-03-04`, retrieved 2026-10-26)
- Started: 2017-03-28 (actual) (ClinicalTrials.gov record NCT03069365, source copy `cardio:ctgov-nct03069365-2019-03-04`, retrieved 2026-10-26)
- Primary completion: 2018-02-20 (actual) (ClinicalTrials.gov record NCT03069365, source copy `cardio:ctgov-nct03069365-2019-03-04`, retrieved 2026-10-26)
- Completion: 2018-06-05 (actual) (ClinicalTrials.gov record NCT03069365, source copy `cardio:ctgov-nct03069365-2019-03-04`, retrieved 2026-10-26)
- Results first posted: 2019-03-04 (ClinicalTrials.gov record NCT03069365, source copy `cardio:ctgov-nct03069365-2019-03-04`, retrieved 2026-10-26)
- Countries: United States; Canada; Germany; Greece; Italy; Poland; Puerto Rico; South Korea; Spain; Sweden (ClinicalTrials.gov record NCT03069365, source copy `cardio:ctgov-nct03069365-2019-03-04`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct03069365-2019-03-04`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir in Adults With Chronic Hepatitis C Virus Genotype 1 - 6 Infection and Renal Impairment
- Acronym: EXPEDITION-5
- Condition: Hepatitis C Virus (HCV)
- Intervention (Drug): Glecaprevir/pibrentasvir
- Lead sponsor: AbbVie
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Chronic kidney disease (CKD) (`cardio:chronic-kidney-disease`)
- Registry lists this organization as the lead sponsor: AbbVie (`cardio:org-abbvie`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and safety of glecaprevir/pibrentasvir in renally impaired patients with chronic HCV infection (`cardio:pubmed-31821716`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 426d746f2685754e24e41d14e893eca4c575d9cb8dc5a37febdadbd79fbb6ceb
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
